Collaboratory of AIDS Researchers for Eradication (CARE)

摘要 尽管抗逆转录病毒疗法(Art)取得了临床上的成功，但更多的人感染了人类 比起每天感染免疫缺陷病毒(HIV)，开始抗逆转录病毒治疗。自2011年成立以来，马丁·德莱尼 合作计划在治愈艾滋病毒方面取得了重要进展，这是一项亟需的努力 全面抗击艾滋病大流行。艾滋病合作实验室2016年科学议程 根除研究人员(CARE)寻求更快地推进延迟中断和 进入临床测试的许可。我们假设艾滋病毒的潜伏状态可以逆转，从而使抗原性 病毒蛋白被表达，这种干预必须战略性地与免疫疗法相结合，以 允许清除从潜伏期中出现的细胞。这一战略的有效实施可望 导致根除持续的艾滋病毒感染，治愈艾滋病。我们集团现在拥有大量的 以前没有在这个问题上发挥作用的专业知识，包括扩大的小组的技能和工具 医药合作伙伴。我们的初步努力将集中在促进临床试验的主要目标上 根除疗法：检测HIV抗原阳性细胞(IRF I)，清除HIV抗原阳性细胞(IRF 二)、揭示和清除未见的艾滋病毒(IRF 3)。 我们设想了一个迭代的过程，包括在体外、临床前和临床实验中获得的见解 继续推进下一步的临床开发，重要的是反馈给科学家 改进他们的工作，验证分析或假设，并探索新的方向。我们致力于工作 在一个灵活的计划中，能够根据我们的发现改变我们的研究进程，确信 我们将共同推动最终根除艾滋病毒感染的进展。

Abstract Despite the clinical success of antiretroviral therapy (ART), more people contract human immunodeficiency virus (HIV) infection daily than initiate ART. Since its inception in 2011, the Martin Delaney Collaboratory program has made important advances towards a cure for HIV, a much-needed effort to comprehensively combat the AIDS pandemic. The 2016 scientific agenda of the Collaboratory of AIDS Researchers for Eradication (CARE) seeks to more rapidly advance approaches for latency disruption and clearance into clinical testing. We hypothesize that the latent state of HIV can be reversed such that antigenic viral proteins are expressed, and that this intervention must be strategically combined with immunotherapies to allow the clearance of cells emerging from latency. Effective implementation of this strategy is expected to lead to the eradication of persistent HIV infection, a cure for AIDS. Our group now possesses substantial expertise previously not brought to bear on this problem, including the skills and tools of an expanded group of pharmaceutical partners. Our initial efforts will focus on the key objectives to facilitate clinical trials of eradication therapy: Detection of HIV antigen-positive cells (IRF I), Clearance of HIV antigen-positive cells (IRF II), Revealing and Clearing Unseen HIV (IRF 3). We envision an iterative process with insights gained in ex vivo, pre-clinical and clinical experiments carried forward to enhance the next step in clinical development and, importantly, fed back to scientists to refine their work, validate assays or hypotheses, and explore new directions. We are dedicated to working together in a nimble program, able to alter the course of our research as directed by our discoveries, convinced that together we will catalyze advances that will ultimately lead to the eradication of HIV infection.